EGFR and non-small cell lung carcinoma: Actually, heterogeneous textural parameters derived from baseline 18F-FDG PET/CT are demonstrated to be high predictors of clinical outcomes for NSCLC patients harboring EGFR mutations treated with TKIs (107).